We are live on ! Find out more

ProQR Therapeutics

PRQR

Market cap $234M

1.66 USD

+0.01

0.61%

At close Updated Sep 30, 4:00 PM EDT

1 day

0.61%

5 days

-2.35%

1 month

-22.07%

3 months

-10.75%

6 months

9.93%

Year to date

-16.58%

1 year

-22.07%

5 years

-80.17%

10 years

-75.11%

About: ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.

Employees: 187

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 71.4%

Negative 0%

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

Appointments support ProQR's strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipeline AX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027 ProQR's expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers.

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

ProQR to Participate in Upcoming Investor Conferences in September 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

ProQR to Participate in Upcoming Investor Conferences in September 2026

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

I initiate ProQR Therapeutics N.V. with a Buy rating, driven by strong initial human proof-of-concept for its Axiomer RNA editing platform. The company's AX-0810 achieved 8-fold serum bile acid increases in phase 1, surpassing the 2-fold target and supporting its disease-modifying potential in biliary atresia [BA]. Upcoming catalysts include full phase 1 data for AX-0810 by end-2026, pediatric BA data from China in H1 2027, and phase 1 data for next-gen AX-0811 by end-2026.

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

ProQR Announces Second Quarter 2026 Operating and Financial Results

LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the second quarter ended June 30, 2026, and provided a business update.

ProQR Announces Second Quarter 2026 Operating and Financial Results

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

ProQR Therapeutics (PRQR) has transitioned its RNA editing platform from preclinical promise to demonstrated human pharmacological activity, notably with AX-0810's Phase 1 target engagement data. PRQR differentiates itself by prioritizing NTCP modulation in rare pediatric liver disease (biliary atresia), aiming for a faster, cleaner clinical validation path than competitors. Recent financings, including a $50M direct offering and Eli Lilly's $9.2M investment, extend PRQR's cash runway to mid-2027, supporting multiple clinical programs.

ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR.

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the Company's first investigational Axiomer RNA editing oligonucleotide (EON), in healthy volunteers.

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

ProQR Announces First Quarter 2026 Operating and Financial Results

AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indication Pipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical catalysts Continued advancement of Axiomer platform, including AI-enabled discovery capabilities, partnership with Ginkgo Bioworks, and formation of AI Advisory Board Ended Q1 2026 with € 81.1 million cash and cash equivalents, supporting runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

ProQR Announces First Quarter 2026 Operating and Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™